X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (245) 245
Publication (37) 37
Patent (30) 30
Book Chapter (9) 9
Newspaper Article (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (105) 105
female (86) 86
oncology (85) 85
index medicus (70) 70
middle aged (55) 55
adult (52) 52
breast cancer (46) 46
aged (45) 45
breast neoplasms - drug therapy (38) 38
male (38) 38
cancer (36) 36
human necessities (28) 28
hygiene (28) 28
medical or veterinary science (28) 28
preparations for medical, dental, or toilet purposes (27) 27
treatment outcome (23) 23
animals (22) 22
article (22) 22
breast neoplasms - pathology (22) 22
chemotherapy (22) 22
antineoplastic agents - therapeutic use (21) 21
care and treatment (21) 21
specific therapeutic activity of chemical compounds ormedicinal preparations (21) 21
neoplasms - drug therapy (20) 20
therapy (20) 20
aged, 80 and over (19) 19
breast neoplasms - metabolism (18) 18
antineoplastic combined chemotherapy protocols - therapeutic use (16) 16
medicine & public health (15) 15
research (15) 15
histone deacetylase inhibitors (14) 14
tumors (13) 13
antineoplastic agents - adverse effects (12) 12
cancer therapies (12) 12
cell line, tumor (12) 12
expression (12) 12
apoptosis (11) 11
beer (11) 11
biochemistry (11) 11
breast-cancer (11) 11
chemistry (11) 11
clinical trials (11) 11
compositions thereof (11) 11
culture media (11) 11
enzymology (11) 11
heterocyclic compounds (11) 11
metallurgy (11) 11
mice (11) 11
microbiology (11) 11
microorganisms or enzymes (11) 11
mutation or genetic engineering (11) 11
organic chemistry (11) 11
patients (11) 11
pharmacokinetics (11) 11
propagating, preserving or maintaining microorganisms (11) 11
spirits (11) 11
trial (11) 11
vinegar (11) 11
wine (11) 11
abridged index medicus (10) 10
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
breast neoplasms - genetics (10) 10
dose-response relationship, drug (10) 10
health aspects (10) 10
maximum tolerated dose (10) 10
mutation (10) 10
adjuvant chemotherapy (9) 9
antineoplastic agents - administration & dosage (9) 9
disease-free survival (9) 9
histone deacetylase (9) 9
medical research (9) 9
melanoma (9) 9
phase-ii (9) 9
receptor, erbb-2 - metabolism (9) 9
suberoylanilide hydroxamic acid (9) 9
cell biology (8) 8
cell lung-cancer (8) 8
differentiation (8) 8
drug therapy (8) 8
enzyme inhibitors - pharmacology (8) 8
fatigue (8) 8
melanoma - drug therapy (8) 8
neoplasm metastasis (8) 8
neoplasm staging (8) 8
protein kinase inhibitors - therapeutic use (8) 8
receptors, estrogen - metabolism (8) 8
risk factors (8) 8
solid tumors (8) 8
survival (8) 8
tamoxifen (8) 8
trastuzumab (8) 8
valproic acid (8) 8
activation (7) 7
antineoplastic agents - pharmacology (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
apoptosis - drug effects (7) 7
cancer research (7) 7
devices for introducing media into, or onto, the body (7) 7
devices for producing or ending sleep or stupor (7) 7
devices for transducing body media or for taking media fromthe body (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2128 - 2135
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 11/2011, Volume 130, Issue 2, pp. 437 - 447
Journal Article
Expert Review of Anticancer Therapy, ISSN 1473-7140, 04/2007, Volume 7, Issue 4, pp. 583 - 598
Journal Article
American Heart Journal, ISSN 0002-8703, 2017, Volume 188, pp. 87 - 92
Background Trastuzumab (TZB) is an established therapy for HER2 positive breast cancer. The use of TZB is commonly associated with cardiotoxicity manifesting... 
Cardiovascular | ADJUVANT CHEMOTHERAPY | CARDIAC & CARDIOVASCULAR SYSTEMS | INHIBITION | VINORELBINE | MULTICENTER PHASE-II | CARDIAC DYSFUNCTION | EXPERIENCE | HIGH-DOSE CHEMOTHERAPY | INDUCED CARDIOMYOPATHY | COMBINATION | PACLITAXEL | Prospective Studies | Trastuzumab - therapeutic use | Humans | Middle Aged | Carbazoles - administration & dosage | Stroke Volume - drug effects | Trastuzumab - adverse effects | Treatment Outcome | Antineoplastic Agents - therapeutic use | Cardiotoxicity - etiology | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Breast Neoplasms - drug therapy | Ventricular Dysfunction, Left - chemically induced | Adrenergic alpha-1 Receptor Antagonists - administration & dosage | Ventricular Dysfunction, Left - physiopathology | Ventricular Dysfunction, Left - prevention & control | Dose-Response Relationship, Drug | Breast Neoplasms - complications | Antineoplastic Agents - adverse effects | Adult | Female | Propanolamines - administration & dosage | Cardiotoxicity - prevention & control | Lisinopril - administration & dosage | Heart | Chemotherapy | Lisinopril | Cardiotonic agents | Angiotensin | Clinical trials | Breast cancer | Cancer | Cardiac glycosides | Phosphates | Anthracyclines | Adjuvant treatment | Therapy | Laboratories | Syngeneic grafts | Cardiomyopathy | Metastasis | Design analysis | Cancer therapies | Incidence | Prevention | Ultrasonic imaging | Epidermal growth factor | Peptidyl-dipeptidase A | Phosphate | Xenografts | Heart diseases | Continuity (mathematics) | Failure | Automation | Echocardiography | Mortality | Exposure | Patients | ErbB-2 protein | Inhibitors | Converting | Anthracycline | Medical prognosis | Breast | Ventricle | Trastuzumab | Ejection | chemotherapy-induced cardiotoxicity | heart failure | cardio-oncology
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 533 - 538
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 10/2019, Volume 74, Issue 13, pp. 1737 - 1738
Journal Article
Breast Cancer Research, ISSN 1465-5411, 12/2015, Volume 17, Issue 1, pp. 26 - 26
Introduction: The emergence of hormone therapy resistance, despite continued expression of the estrogen receptor ( ER), is a major challenge to curing breast... 
ACTIVATION | THERAPY | ONCOLOGY | ESTROGEN-RECEPTOR-ALPHA | GENE-EXPRESSION | C-MYC | PHASE-II | MECHANISMS | PROGESTERONE-RECEPTOR | TRICHOSTATIN-A | CELL-LINE | Estradiol - analogs & derivatives | Receptors, Estrogen - metabolism | Apoptosis - drug effects | Proto-Oncogene Proteins p21(ras) - genetics | Humans | Transcriptome | Cell Survival - genetics | Apoptosis - genetics | Gene Expression Profiling | Breast Neoplasms - metabolism | Proto-Oncogene Proteins c-bcl-2 - metabolism | Female | Transcription, Genetic | Antineoplastic Agents - pharmacology | Estradiol - pharmacology | Disease Models, Animal | Proto-Oncogene Proteins p21(ras) - metabolism | Cell Survival - drug effects | Gene Expression | Histone Deacetylases - metabolism | Breast Neoplasms - drug therapy | Proto-Oncogene Proteins c-myc - metabolism | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Tamoxifen - pharmacology | Cell Line, Tumor | Protein Binding | Tamoxifen - analogs & derivatives | Histone Deacetylase Inhibitors - pharmacology | Ligands | Cell Proliferation - drug effects | Proto-Oncogene Proteins c-myc - genetics | Proto-Oncogene Proteins c-bcl-2 - genetics | Medical research | Epigenetic inheritance | Estrogen | Medicine, Experimental | Breast cancer | Genetic engineering | Progesterone | Hormones | Genetic transcription | Tamoxifen | Apoptosis
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 92 - 12
Journal Article
Cancer Letters, ISSN 0304-3835, 2009, Volume 280, Issue 2, pp. 184 - 191
Abstract Histone deacetylase (HDAC) inhibitors are a novel class of anti-tumor agents with a potential role in the treatment of breast cancer. In ER-positive... 
Hematology, Oncology and Palliative Medicine | Estrogen receptor | HDAC inhibitors | Breast cancer | Histone deacetylases | Progesterone receptor | Anti-estrogen therapy | HDAC | PREDICTIVE-VALUE | HUMAN BREAST-CANCER | FACTOR BINDING-PROTEINS | CHAPERONE FUNCTION | ONCOLOGY | ADJUVANT ENDOCRINE THERAPY | ESTROGEN-RECEPTOR-ALPHA | GENE-EXPRESSION | PROGESTERONE-RECEPTOR | POSTMENOPAUSAL WOMEN | ONCOLOGY TECHNOLOGY-ASSESSMENT | Neoplasms, Hormone-Dependent - metabolism | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Signal Transduction | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Receptors, Estrogen - antagonists & inhibitors | Histone Deacetylases - metabolism | Clinical Trials as Topic | Breast Neoplasms - drug therapy | Breast Neoplasms - metabolism | Drug Synergism | Estrogen Antagonists - administration & dosage | Estrogen Antagonists - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Cell Line, Tumor | Female | Histone Deacetylase Inhibitors | Neoplasms, Hormone-Dependent - drug therapy | Heat shock proteins | Progesterone | Analysis | Estrogen | Enzymes | Transcription factors | Disease | Clinical trials | Endocrine therapy | Cancer therapies | Studies | Chemotherapy | Womens health | Protein expression | Tumorigenesis | Tumors | Index Medicus
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, p. e68973
Hormonal therapy resistance remains a considerable barrier in the treatment of breast cancer. Activation of the Akt-PI3K-mTOR pathway plays an important role... 
SURVIVAL | ACTIVATION | HEAT-SHOCK-PROTEIN-90 | PATHWAY | PHOSPHORYLATION | MULTIDISCIPLINARY SCIENCES | KINASE | PHASE-II | DEGRADATION | CHAPERONE FUNCTION | TRICHOSTATIN | Receptors, Estrogen - metabolism | Apoptosis - drug effects | Humans | RNA, Messenger - genetics | Endoplasmic Reticulum - metabolism | Receptors, Estrogen - antagonists & inhibitors | Benzofurans - pharmacology | Histone Deacetylases - metabolism | Mitochondria - metabolism | Mitochondria - drug effects | Enzyme Activation - drug effects | Proto-Oncogene Proteins c-akt - genetics | Breast Neoplasms - metabolism | Breast Neoplasms - genetics | Tamoxifen - pharmacology | Cell Line, Tumor | Female | Histone Deacetylase Inhibitors - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Proto-Oncogene Proteins c-akt - metabolism | Hydroxamic Acids - pharmacology | Selective Estrogen Receptor Modulators - pharmacology | Medical research | Care and treatment | RNA | Estrogen | Breast cancer | Tamoxifen | Prevention | Cell death | Cancer cells | Medicine, Experimental | Phenols | Drug therapy | Health aspects | Cancer | Cytochrome | TOR protein | Therapy | Histone deacetylase | Regulators | Chromatin | Toxicity | Estrogens | Cytotoxicity | Oncology | AKT protein | mRNA | Metastasis | Kinases | Proteins | Bioindicators | Inhibition | Immunoglobulins | AKT1 protein | Hematology | Endocrine therapy | siRNA | 1-Phosphatidylinositol 3-kinase | Medicine | Inhibitors | MicroRNAs | Biomarkers | Breast | Combined treatment | Apoptosis
Journal Article